YST-3) used in this study were established by inoculation of fresh tumour tissues from three different patients into BALB/C female nude mice in our laboratory, as previously described (Sawada et al., 1981; . The tumours were cut into small pieces (2-4 mm3) in ice-cold Eagle's minimum essential medium and transplanted s.c. into nude mice by trocar. At the time of these experiments the number of previous tumour tissue passages ranged from 20 to 30. The tumour take rate for all the tumour lines was 90-100%.
CBDCA was supplied by the Drug Synthesis and Chemistry Branch, National Cancer Institute (NCI), USA. CHIP and CDDP were supplied by Bristol-Myers Company. CDDP was dissolved in 0.2ml 0.9% NaCl solution, and CBDCA and CHIP were dissolved in 0.2 ml distilled water. Fifty mgkg-of CBDCA, 25mgkg-1 of CHIP and 6mg kg-1 of CDDP were administered i.p. into tumour-bearing nude mice three times with intervals of 4 days. Control mice were injected i.p. with 0.2ml 0.9% NaCl. The dosages used in this experiment were based on the results in the NCI File Comparative studies of cisplatin and platinum containing analogues reported by the Platinum Analogue Working Group in 1980.
When the tumours became palpable and were growing progressively, experimental mice were randomized into test groups of 5-10 mice (one tumour each). The size of the implant was measured with slide calipers twice a week, and the volume (V), in mm3, was calculated by the formula described by Houchens et al. (1978) : V= Wx L x 1/2, where W and L are the width and length in mm. For comparison with different groups, the relative tumour volume (RV) for each group was calculated from the formula RV= Vi/Vo, where Vi = the mean tumour volume at any given time and Vo = the mean initial tumour volume when treatment was begun. TIC (ratio of RV for treated mice to RV for control mice, multiplied by 100) was calculated at each measurement.
Treatment of the YST-1 tumours was initiated 25 days post transplantation. As shown in Figure Table I . Arrows indicate injection of each drug. the growth of YST-1 (Table I) . Treatment of the YST-2 tumour was initiated 22 days post transplantation. As shown in Figure 1 , CDDP, CBDCA and CHIP all significantly suppressed the growth of YST-2. The tumour disappeared in one of 7 mice treated with CDDP, in 2 of 10 mice treated with CBDCA and in one of 9 mice treated with CHIP. No statistical difference in the antitumour activity of these drugs was observed between CDDP-, CBDCA-, CHIP-treated groups (Table I) .
Treatment of the YST-3 tumour was initiated 28 days post transplantation. As shown in Figure 1 , CDDP, CBDCA and CHIP all suppressed tumour growth. Although the YST-3 tumour seemed to respond more quickly to CDDP and CBDCA, no statistical difference in the T/C values was observed between the CDDP-, CBDCA-, and CHIP-treated groups (Table I) . While tumours YST-2 and YST-3 exhibit broadly comparable sensitivity to CDDP and the two analogues, YST-1 is substantially more sensitive to CDDP than to CBDCA or CHIP. This result reflects the clinical response of that small proportion (25%) of ovarian cancer patients who had received CDDP treatment and responded subsequently to CBDCA (Evans et al., 1983) .
Human nude mice models may be more clinically predictive of platinum response than conventional rodent transplant models.
Of course it is impossible to select a drug as the most effective against yolk sac tumours on the basis of efficacy at a single dose. The dosages used in the present study were less than the lethal dose for nude mice and about one-third of the LD50 for conventional mice, reported by other investigators (Wilkinson et al., 1978; Bradner et al., 1980; Schurig et al., 1980; Shepherd et al., 1980; Lelieveld et al., 1984) . The doses used here are in the right range because they appear equally toxic in terms of mean body weight as a percentage of starting weight. The largest decrease (15%) in mean body weight was observed on days 8-12. But the decrease was not statistically different between the CDDP-, CBDCA-, and CHIP-treated groups. No mice died during this experiment.
The point of the new platinum analogues is amelioration of the particular problem of renal toxicity. Since our primary interest was to examine the anti-tumour activity of CDDP, CBDCA and CHIP, we did not evaluate renal damage in the mouse. Detailed discription of the specific toxicity of new platinum analogues has been given by other investigators Boven et al., 1985) .
More data are required for a detailed comparison of the antitumour effects of platinum analogues against ovarian cancer. Further studies are in progress using newly established epithelial ovarian tumours (Sawada et al., 1985) , because germ cell tumours of the ovary have a different spectrum of chemotherapeutic sensitivities from epithelial ovarian cancer (Hakes, 1984) .
